Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV Clinical Trial of the ACYW135 Group Meningococcal Polysaccharide-Conjugated Vaccine (CRM197 Vector)

NCT07743411 is registered in ClinicalTrials.gov with CanSino Biologics Inc. as lead sponsor.

NCT NCT07743411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07743411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV Clinical Trial of the ACYW135 Group Meningococcal Polysaccharide-Conjugated Vaccine (CRM197 Vector)
Lead sponsor
CanSino Biologics Inc.
Phase
Observational
Overall status
Not yet recruiting
Start date
September 15, 2026
Completion date
September 15, 2028
Enrollment
180 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

epidemic meningitis